FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with…
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Breast medical oncologist Banu Arun, M.D., discusses breast cancer risk factors and prevention.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.
More people in their 40s, 30s and even 20s are diagnosed with colorectal cancer each year, and those diagnoses tend to have more advanced stages…